Editing Naloxone (section)

====Intramuscular or subcutaneous====
Naloxone can also be administered via [[intramuscular]] or [[subcutaneous injection]]. The onset of naloxone provided through this route is 2 to 5 minutes with a duration of around 30–120min.<ref>{{cite web | title = Naloxone for Treatment of Opioid Overdose | date = October 2016 | url = https://www.fda.gov/media/100429/download | author = Advisory Committee | work = Insys Development Company, Inc. | publisher = U.S. Food and Drug Administration }}</ref> Naloxone administered intramuscularly are provided through pre-filled syringes, vials, and auto-injector. A hand-held auto-injector is pocket-sized and can be used in non-medical settings such as in the home.<ref name="special circum 2015"/> It is designed for use by laypersons, including family members and caregivers of opioid users at risk for an opioid emergency, such as an overdose.<ref name="FDA News Release">{{cite press release |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm391465.htm|title=FDA approves new hand-held auto-injector to reverse opioid overdose |publisher = U.S. [[Food and Drug Administration]] (FDA) |archive-url= https://web.archive.org/web/20150716003000/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm391465.htm|archive-date=16 July 2015|access-date=20 July 2015|url-status=dead}}</ref> According to the FDA's [[National Drug Code]] Directory, a generic version of the auto-injector began to be marketed at the end of 2019.<ref>{{cite web|url=https://ndclist.com/ndc/72853-051/package/72853-051-02|title=NDC 72853-051-02 Naloxone Hydrochloride Auto-injector|website=NDClist.com|access-date=21 March 2020|archive-date=21 March 2020|archive-url=https://web.archive.org/web/20200321212308/https://ndclist.com/ndc/72853-051/package/72853-051-02|url-status=dead}}</ref>